Literature DB >> 9886077

Dual roles of proteasome in the metabolism of presenilin 1.

T Honda1, K Yasutake, N Nihonmatsu, M Mercken, H Takahashi, O Murayama, M Murayama, K Sato, A Omori, S Tsubuki, T C Saido, A Takashima.   

Abstract

Presenilin 1 (PS1) has been identified as a causative gene for most early-onset familial Alzheimer's disease. Biochemical studies revealed that PS1 exists predominantly as two processed fragments in cells and brain tissues. We prepared stably transfected cells expressing the wild-type and familial Alzheimer's disease-associated mutants of PS1 and investigated the enzyme that participates in the metabolism of PS1. After treatment of the cells with proteasome inhibitors, the full-length PS1 was significantly accumulated. The levels of N- and C-terminal fragments were also increased. The accumulation of PS1 with a deletion of exon 10, which is unable to be processed, on treatment of the transfected cells with lactacystin indicated that proteasome can degrade full-length PS1. A synthetic peptide that includes the processing region of PS1 was cleaved by 20S proteasome at the putative processing sites after Met288 and Glu299. Metabolic labeling experiments showed that the appearance of the N-terminal fragment was attenuated by the inhibitor. Finally, 28-kDa N- and 20-kDa C-terminal fragments were generated by purified PS1 in vitro. These data indicated that the proteasome pathway is involved in PS1 processing. These results demonstrate that the proteasome pathway plays dual roles in processing and degradation of PS1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886077     DOI: 10.1046/j.1471-4159.1999.0720255.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Presenilins: structural aspects and posttranslational events.

Authors:  F Checler
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

3.  Ongoing DNA synthesis in the rat cerebral cortex is regulated by a proteolytic pathway independent of the proteasome and calpains.

Authors:  J Sebastián Yakisich; Ake Sidén; Mabel Cruz
Journal:  Invest New Drugs       Date:  2009-03-17       Impact factor: 3.850

Review 4.  Proteasome inhibition: a new anti-inflammatory strategy.

Authors:  Peter J Elliott; Thomas Matthias Zollner; Wolf-Henning Boehncke
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

5.  Ubiquilin regulates presenilin endoproteolysis and modulates gamma-secretase components, Pen-2 and nicastrin.

Authors:  Leann K Massey; Alex L Mah; Mervyn J Monteiro
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

6.  Presenilin-1 regulates induction of hypoxia inducible factor-1α: altered activation by a mutation associated with familial Alzheimer's disease.

Authors:  Rita De Gasperi; Miguel A Gama Sosa; Stella Dracheva; Gregory A Elder
Journal:  Mol Neurodegener       Date:  2010-09-23       Impact factor: 14.195

7.  Presenilin-2 in the cynomolgus monkey brain: investigation of age-related changes.

Authors:  Nobuyuki Kimura; Shin' ichiro Nakamura; Fumiko Ono; Ippei Sakakibara; Yoshiyuki Ishii; Shigeru Kyuwa; Yasuhiro Yoshikawa
Journal:  Primates       Date:  2004-02-18       Impact factor: 2.163

8.  Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation.

Authors:  A L Mah; G Perry; M A Smith; M J Monteiro
Journal:  J Cell Biol       Date:  2000-11-13       Impact factor: 10.539

9.  Conformational Changes in Transmembrane Domain 4 of Presenilin 1 Are Associated with Altered Amyloid-β 42 Production.

Authors:  Aya Tominaga; Tetsuo Cai; Shizuka Takagi-Niidome; Takeshi Iwatsubo; Taisuke Tomita
Journal:  J Neurosci       Date:  2016-01-27       Impact factor: 6.167

Review 10.  Neuronal death in Alzheimer's disease and therapeutic opportunities.

Authors:  Rossen Donev; Martin Kolev; Bruno Millet; Johannes Thome
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.